<head></head><body><div class="content gradient-lighter">
  <div class="content-header">
    <div class="container">
      <button id="button-back"></button>
      <div class="title"><rich-text id="70c55f79-c1b3-45cd-9299-04e513779ac0">Disease</rich-text></div>
    </div>
    <div class="subtitle"><rich-text id="0db6d130-33cd-492e-8c44-8922e6e9a4f7">Disease Variability and Heterogeneity</rich-text></div>
  </div>

  <div class="toggable-buttons-container tabbed">
    <button data-slide="0" data-group="main" data-toggable-button="" class="toggable-button "><rich-text id="7a001f78-a0a4-4ff1-af67-3a0fb79db63f">Symptom Variability</rich-text></button>
    <button data-slide="1" data-group="main" data-toggable-button="" class="toggable-button "><rich-text id="6438b01b-c70d-4440-8d59-dbed0620c7f4">Brain Alteration Variability</rich-text></button>
    <button data-slide="2" data-group="main" data-toggable-button="" class="toggable-button "><rich-text id="973c38ec-427e-4076-a4aa-cb677025cd79">Treatment Variability</rich-text></button>
  </div>

  <div class="tabbed-top">
    <!-- BEGIN Symptom Variability in Bipolar Disorder -->
    <div class="text-container toggable-container" data-slide="0" data-group="main">
      <h1><rich-text id="e08b6f46-2a59-4088-bb49-cf2f90f326d7">Symptom Variability in Bipolar Disorder</rich-text></h1>
      <div class="panel">
        <p><rich-text id="e49c3366-e03f-404d-9008-9c63c64abad2">The complexity of connections between symptoms means there are<b></b>that all qualify for an Bipolar Disorder diagnosis.</rich-text></p>
        <p><rich-text id="fcc1c93a-c19e-4937-874b-30fbdc8cc4f5">Using the Diagnostic and Statistical Manual of Mental Disorder (DSM), patients need to exhibit 5 or more of the below symptoms during a 2-week period. At least one of which must be depressed mood or anhedonia, to qualify for a Bipolar Disorder diagnosis<sup></sup>.</rich-text></p>
      </div>

      <div class="panel transition duration-500 ease-in-out" id="info-panel"><rich-text id="705a3558-61ad-4b61-a58c-4525a75a2455">Click on each region to learn more</rich-text></div>

      <svg id="interactive-map-svg" width="100%" viewBox="0 0 960 540" preserveAspectRatio="xMidYMid meet" class="my-4"></svg>

      <!-- </div> -->

      <div class="suggested-node">
        <button class="dotted-button" data-node="mania" data-content="symptoms-alterations" data-state="optimal-one"><rich-text id="de0a861e-5ee2-4d61-8878-5881e6014879">For more detailed information on Manic symptoms please see</rich-text><p><rich-text id="c393bae7-479a-4bef-8bfe-788672e40e4b">Mania</rich-text></p>
        </button>
      </div>
      <div class="suggested-node">
        <button class="dotted-button" data-node="hypomania" data-content="symptoms" data-state="optimal-two"><rich-text id="0b2ba4d1-e740-4ea5-8f6a-f5d58200a924">For more detailed information on Hypomanic symptoms please see</rich-text><p><rich-text id="db912701-c062-4e88-ad59-e25a0dbd9ea3">Hypomania</rich-text></p>
        </button>
      </div>
      <div class="suggested-node">
        <button class="dotted-button" data-node="depression" data-content="symptoms"><rich-text id="6666490d-b69d-429a-88ea-d7948cb1743b">For more detailed information on Depressive symptoms please see</rich-text><p><rich-text id="5fd15fa1-6fd6-402f-935f-c970d2d7d6b3">Depression</rich-text></p>
        </button>
      </div>

      <div class="panel">
        <h3><rich-text id="4b2af244-fb0a-4efa-9a23-deb906c175bc">Age variability</rich-text></h3>
        <ul class="list"><rich-text id="82c7ddaf-1d76-46b4-8cfc-a798009da6e4"><li>Longer episodes and shorter breaks between episodes in older people with BD<sup></sup>.</li><li>Younger people have higher intrasubject variability in response time<sup></sup>, relating to deficits in maintaining concentration and arousal<sup></sup>.</li><li>Affrontive symptoms are associated more strongly with older patients<sup></sup>.</li></rich-text></ul>
        <h3><rich-text id="c534169b-2dad-4501-b017-d1610f440efb">Cognitive and Functional Variably</rich-text></h3>
        <ul class="list"><rich-text id="e47119fd-e9b5-4a04-8199-b26cf8fb8672"><li>It has been shown that patients with bipolar disorder exhibit differences in cognitive abilities<sup></sup>.</li><li>Cognitive abnormalities can involve attention, memory and executive functioning<sup></sup>, possibly due to brain abnormalities seen in some patients<sup></sup>.</li><li>Functional impairment has been shown to vary depending on mood symptoms experienced by patients with bipolar disorder<sup></sup>.</li></rich-text></ul>
        <h3><rich-text id="678054b5-e28f-4eb0-a843-7c32e824dd9b">Gender variability</rich-text></h3>
        <ul class="list"><rich-text id="5c0795b6-1592-4c9f-bb41-d9f8952c6c6a"><li>Men with BD 1 more likely to have a manic episode at the beginning of the disorder, whereas women are more likely to have depressive episodes at the early stages of the disorder<sup></sup>.</li></rich-text></ul>
        <h3><rich-text id="976d04ed-79c3-4e68-a603-73cb575a5559">Comorbidity Variability</rich-text></h3>
        <ul class="list"><rich-text id="d7230137-5707-4438-866b-06c75d301bed"><li>Substance abuse and dependence is more common in men than women with BD<sup></sup>.</li><li>Antisocial behaviors are more likely in men than women with BD<sup></sup>.</li><li>Women are more likely to experience changes in appetites<sup></sup>and develop eating disorders<sup></sup>.</li><li>Early onset and rapid cycling is associated with higher incidence of anxiety<sup></sup>.</li><li>Changes in the autonomic nervous system and heart rate<sup></sup>.</li><li>Comorbid conditions are related to age of onset and familial loading<sup></sup>.</li><li>Remitting episodic course is more likely to respond to Lithium and not develop comorbidities<sup></sup>.</li></rich-text></ul>
      </div>

      <div class="references panel">
        <h4><rich-text id="c70274f5-3d09-48eb-b7ec-bcd550387963">References</rich-text></h4>
        <ol class="list"><rich-text id="5c4c98ca-311a-41dc-90f7-bf822d002593"><li>Angst J. Bipolar disorders in DSM-5: strengths, problems and perspectives. International Journal of Bipolar Disorders. 2013:1:12</li><li>Depp C.A., Jeste D.V. Bipolar disorder in older adults:a critical review. Bipolar Disorders. 2004:6;343-367</li><li>Brotman M.A., Rooney M.H., Skup M,. Pine D.S., Leibenluft E. Increased intrasubject variability in response time in youths with bipolar disorder and at-risk family members. J. Am. Acad. Child Adolesc. Psychiatry. 2009;48(6)628-635</li><li>O'Rourke N., Sixsmith A., King D.B., Yaghoubi-Shahir H., Canham S.L., BADAS., Development and validation of the BDSx: a breif measure of mood and symptom variability for use with adults with bipolar disorder, Int J Bipolar Disord. 2016;4(8):1-8</li><li>Sole B., Jimenez E., Torrent C., Bonnin C.M., Torres I., Reinares M., Preigo A., Salamero M., Colom F., Varo C., Vieta E., Martinez-Aran A.,. Cognative variability in bipolar II disorder: who is cognitively impaired and who is preserved. . Bipolar disorders. 2016:18;288-299</li><li>Deep C.A., Salva G.N., Vergel de Dios L.A., Mausbach B.T., Palmer B.W. Affective symptoms and intra-individual variability in the short term course of cognitive functioning in bipolar disorder. Psychol Med. 2012;42(7)1409-1416.</li><li>Li H, Mukherjee D., Krishnamurthy V.B., Millett C., Ryan K.A., Zhang L., Saunders E.F.H., Wang M. Use of ecological momentary assessement to detect variability in mood, sleep and stress in bipolar disorder. BMC Res Notes. 2019;12(791)1-7</li><li>Kawa I., Carter J.D., Joyce P.R., Doughty C.J., Frampton C.M., Wells J.E., Walsh A.E.S., Olds R.J. Gender differences in bipolar disorder: age of onset, course, comorbitiy, and system presentation. Bipolar disorders. 2005;7:199-125</li><li>Alda M., The phenotypic spectra of bipolar disorder. European Neuropsychopharmacology. 2004;14:94-99</li><li>Voss A., Baier V., Schulz S., Bar K.J., Linear and nonlinear methods for analyses of cardiovascular variability in bipolar patients. Bipolar disorder. 2006:8;411-452</li></rich-text></ol>
      </div>
    </div>
    <!-- END Symptom Variability in Bipolar Disorder -->

    <!-- BEGIN Brain Alteration Variability in Bipolar Disorder -->
    <div class="text-container toggable-container" data-slide="1" data-group="main">
      <h1><rich-text id="edffc05e-ffab-4166-947f-3e15c3c87bf1">Brain Alteration Variability in Bipolar Disorder</rich-text></h1>
      <p class="panel"><rich-text id="b2c57073-b528-4dae-974e-a8a3ab1445f0">Variability within the brains of bipolar disorder patients can be due to a variety of reasons. These include: genetic and environmental factors<sup></sup>, the treatment received<sup></sup>and substance use<sup></sup>.</rich-text></p>

      <p class="panel transition duration-500 ease-in-out text-center" id="brain-info-panel"><rich-text id="e9d67315-eadc-48b4-b9e7-91c8b68c6ae0">Click on each region to learn more about its involvement in bipolar</rich-text></p>

      <svg id="interactive-svg" class="shadow rounded-lg" width="100%" viewBox="0 0 960 480" preserveAspectRatio="xMidYMid meet"></svg>

      <div class="suggested-node">
        <button class="dotted-button" data-node="disease" data-content="brain-comparison"><rich-text id="14bcb1af-79b6-47b2-9f4d-d59a977274cd">For more detailed information on the brain please see</rich-text><p><rich-text id="0d1e2ea6-ef22-49ad-b185-02f8209343ed">Healthy vs. Bipolar brain</rich-text></p>
        </button>
      </div>

      <div class="references panel">
        <h4><rich-text id="43b8a2ea-1226-4d2d-8145-e00f474d608d">References</rich-text></h4>
        <ol class="list"><rich-text id="e72c25a5-b9ed-4a4f-94c9-8dd1138f8213"><li>Frazier J.A., Chiu S., Breeze J.L., Makris N., Lange N., Kennedy D.N., Herbert M.R., Bent E.K., Koneru V.S., Dieterich M.E., Hodge S.M., Rauch S.L, Grant P.E., Cohen B.M., Seidman L.J., Caviness V.S., Beirderman J., Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. Am J. Psychiatry. 2005;162:1256-1265</li><li>Bearden C.E., Thompson P.M, Dalwani M., Hayashi K.M., Lee A.D., Nicoletti M., Trakhtenbroit M., Glahn D.C., Brambilla P., Sassi R.B., Mallinger A.G., Frank E., Kupfer D.J., Soares J.C. Greater Cortical Gray Matter Density in Lithium-Treated Patients with Bipolar Disorder. Biol Psychiatry. 2007;62:7–16</li><li>Yucel K., Taylor V.H., McKinnon M.C., MacDonald K., Alda M., Young L.T., MacQueen G.M. Bilateral Hippocampal Volume Increase in Patients with Bipolar Disorder and Short-term Lithium Treatment. Neuropsychopharmacology. 2008;33:361–367</li><li>Hwang J., Lyoo I.K., Dager S.R., Friedman S.D., Oh, J.S., Lee, J.Y., Kim, S.J., Dunner, D.L. Renshaw, P.F. Basal Ganglia Shape Alterations in Bipolar Disorder. Am J Psychiatry. 2006;163:276–285</li></rich-text></ol>
      </div>
    </div>
    <!-- END Brain Alteration Variability in Bipolar Disorder -->

    <!-- BEGIN Treatment Variability in Bipolar Disorder -->
    <div class="text-container toggable-container" data-slide="2" data-group="main">
      <h1><rich-text id="f1e31069-56b1-49a3-898d-da5a7836bd40">Treatment Variability in Bipolar Disorder</rich-text></h1>
      <p class="panel"><rich-text id="9c574c6d-671d-4abc-8808-325835e548d2">Bipolar disorder is complex, comprises of subtypes that responds differently to different treatments ,<sup></sup>, with an estimated third of patients not responding to treatment at all<sup></sup>. Approximately 44% of people with bipolar disorder experience relapse within in 1 year and<sup></sup>increasing to 73% in 5 years<sup></sup>.</rich-text></p>

      <div class="toggable-buttons-container mt-4">
        <button data-slide="0" data-group="treatment" data-toggable-button="" class="toggable-button  padded"><rich-text id="e912dc51-8b84-466d-8218-4ed0a5f61eae">Pharmacological</rich-text></button>
        <button data-slide="1" data-group="treatment" data-toggable-button="" class="toggable-button  padded"><rich-text id="2324c909-d3c0-4368-b68e-3fbb877a1d26">Psychotherapy</rich-text></button>
        <button data-slide="2" data-group="treatment" data-toggable-button="" class="toggable-button  padded"><rich-text id="b7c00c5a-0f38-4f8d-b6eb-bdc9b17d7ff3">Other</rich-text></button>
      </div>
      <!-- START Pharmacological -->
      <div class="toggable-container" data-slide="0" data-group="treatment">
        <div class="flex space-x-2 flex-wrap justify-center">
          <div class="panel flex-1 space-y-2" style="flex-basis: 30%">
            <h3><rich-text id="f8c7ec98-d498-4909-8be3-3f0e6df55696">Lithium</rich-text></h3>
            <ul class="list"><rich-text id="9335ffe1-ec5e-4f78-a9c8-93811c3e73db"><li>49% of patients respond with<sup></sup>a reduction manic episodes by up to 38% and depressive relapse episodes by up to 28%<sup></sup></li><li>Side effects include reduced renal function and hyperparathyroidism<sup></sup>.</li><li>20-40% of BD suffers do not respond to lithium treatment<sup></sup>.</li><li>Lithium has been shown to reduce suicide by up to 50%<sup></sup>.</li></rich-text></ul>
          </div>
          <div class="panel flex-1 space-y-2" style="flex-basis: 30%">
            <h3><rich-text id="8f99858b-cc0a-44d4-ac70-c1c56639ee2f">First Generation</rich-text><br><rich-text id="feb9aeb5-a382-40ff-9b7c-3e45709347ac">Antipsychotics</rich-text></h3>
            <ul class="list"><rich-text id="43b71b30-75b2-4032-8dae-47bcb5a2752a"><li>Average 47% response rate<sup></sup>.</li><li>Long-term use not advised due to negative side effects<sup></sup>.</li></rich-text></ul>
          </div>
          <div class="panel flex-1 space-y-2" style="flex-basis: 30%">
            <h3><rich-text id="b2d38059-e429-42af-9ad9-378dd7d5b3ca">Second Generation</rich-text><br><rich-text id="9f9c7192-7bcc-4bb3-95d7-8378ec7cb666">Antipsychotics</rich-text></h3>
            <ul class="list"><rich-text id="c409b8e5-66e9-4aa9-8979-2ed91be79fc4"><li>Average 28% of patients were stable for over a year<sup></sup>.</li><li>However second generation antipsychotics have been linked to higher suicidal ideation<sup></sup>.</li></rich-text></ul>
          </div>
          <div class="panel space-y-2" style="flex-basis: 33%">
            <h3><rich-text id="8a69f3af-04c1-47ff-a26a-8b1997735b15">Anticonvulsants</rich-text></h3>
            <ul class="list"><rich-text id="3cf3e428-30bc-4a0c-9851-1105b789bcac"><li>There are a limited number of anticonvulsants that are effective mood stabilizers<sup></sup>.</li><li>Average 48% response rate<sup></sup>with 37-48% failure rate in comparison to lithium<sup></sup>.</li></rich-text></ul>
          </div>
          <div class="panel space-y-2" style="flex-basis: 33%">
            <h3><rich-text id="2a1dc4e1-e8bf-4195-ab54-1cc8313f202c">Antidepressants</rich-text></h3>
            <ul class="list"><rich-text id="ec1c279b-a06a-4eeb-880a-eafdc01fdfb2"><li>Long term use is not recommended<sup></sup>as their benefits are often minor<sup></sup>and some patients experience increased numbers of manic episodes<sup></sup>, rapid cycling<sup></sup>and dysphoria<sup></sup>with antidepressants</li><li>Risk of spontaneous mania in some patients without antidepressants has been shown to be 14%<sup></sup>.</li></rich-text></ul>
          </div>
        </div>
      </div>
      <!-- END Pharmacological -->

      <!-- START Psychotherapy -->
      <div class="toggable-container" data-slide="1" data-group="treatment">
        <div class="flex space-x-2">
          <div class="panel flex-1 space-y-2">
            <h3><rich-text id="775a5ff7-34a3-48b3-bf3c-4747402ce219">Cognitive behavior Therapy (CBT)</rich-text></h3>
            <ul class="list"><rich-text id="eefcd63f-2785-418e-8425-b89c09119237"><li>Commonly used to treat depression and anxiety disorders<sup></sup>.</li><li>CBT, in combination with medication and psychological support, has been shown to reduce manic and depressive relapses, the length of episodes, hospital admissions<sup></sup>and improve global functioning<sup></sup>but benefits may only be short term<sup></sup>and depend on disease severity<sup></sup>.</li></rich-text></ul>
          </div>
          <div class="panel flex-1 space-y-2">
            <h3><rich-text id="30211e83-8ca7-4157-85cd-aaf6f1ccfcda">Family-Focused Therapy (FFT)</rich-text></h3>
            <ul class="list"><rich-text id="9603f8f5-d1d8-4596-a860-76899d2d5483"><li>Involves educating the patient and family<sup></sup>.</li><li>FFT has shown improvement to adherence to medications through education<sup></sup>.</li><li>FFT is associated with improved recovery times from depressive symptoms,<sup></sup>but has been shown to have little effect on manic symptoms<sup></sup>.</li><li>Multiple family sessions are required which are not always possible<sup></sup>.</li></rich-text></ul>
          </div>
          <div class="panel flex-1 space-y-2">
            <h3><rich-text id="6791f1b0-0d5c-4018-89ba-5c03dccb387d">Interpersonal and Social Rhythm Therapy (IPSRT)</rich-text></h3>
            <ul class="list"><rich-text id="dc74e761-b451-44f6-8597-7b5917a784ba"><li>Aims to resolve any interpersonal problems that occurred during the persons most recent episode through regulating improve day and night-time routines<sup></sup>.</li><li>IPSRT has been shown to increase time between episodes if treatment was given during the acute phase<sup></sup>.</li></rich-text></ul>
          </div>
        </div>
      </div>
      <!-- END Psychotherapy -->

      <!-- START Other -->
      <div class="toggable-container" data-slide="2" data-group="treatment">
        <div class="flex space-x-2">
          <div class="panel flex-1 space-y-2">
            <h3><rich-text id="08869d1a-4c62-4ed7-b622-9449529fb4c7">Electroconductive Therapy (ECT)</rich-text></h3>
            <ul class="list"><rich-text id="3abbd3cf-e76a-4c26-b501-e297614ab23e"><li>There is contradictory evidence that ECT improves the rates of hospital admissions<sup></sup>.</li><li>More commonly a second-line treatment for severe bipolar disorder<sup></sup>.</li><li>Approximately 30% of patients with bipolar type 1 respond to ECT treatment<sup></sup>.</li><li>Long times between treatments have been shown to be less effective and maintenance treatment requirements are varied<sup></sup>.</li><li>Negative responses such as cognitive side effects and cardiac problems can occur<sup></sup>.</li></rich-text></ul>
          </div>
          <div class="panel flex-1 space-y-2">
            <h3><rich-text id="626f1bab-0e47-4c79-9a16-6e076b95111e">Omega-3 Fatty acids</rich-text></h3>
            <ul class="list"><rich-text id="a4e50bb4-6290-4200-bea0-6b04fa17a6dc"><li>Have been shown to increase remission times through mild improvements of depressive symptoms in some patients with bipolar disorder<sup></sup>, but no effect on manic symptoms<sup></sup>.</li><li>Results are heavily dependent on the type of fatty acid used, the dose and if additional medications were taken<sup></sup>.</li></rich-text></ul>
          </div>
        </div>
      </div>
      <!-- END Other -->

      <div class="references panel">
        <h4><rich-text id="937f3b2c-bd08-4189-a8f3-6dc1c1c0e7c8">References</rich-text></h4>
        <ol class="list"><rich-text id="57f30761-1d89-4969-b62f-a8139af3912f"><li>Jones S., Psychotherapy of bipolar disorder: a review. Journal of Affective Disorders. 2004;80:101–114.</li><li>Geddes J.R., Miklowitz D.J., Treatment of bipolar disorder. Lancet. 2013;381:1672–82.</li><li>Gitlin M., Treatment-resistant bipolar disorder. Molecular Psychiatry. 2006;11:227–240.</li><li>Fountoulakis K.N., Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives International Journal of Neuropsychopharmacology. 2008;11:999–1029.</li><li>Zarate, C.A., Quiroz J.A. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disorders. 2003;5:217–225.</li><li>Baldessarini R.J., Tondo L., Vázquez G.H., Pharmacological treatment of adult bipolar disorder. Molecular Psychiatry. 2019;24:198–217.</li><li>Young T.J. What is the best treatment for bipolar depression? J Psychiatry Neurosci. 2008;33(6):487-8.</li><li>Miklowitza, D.J., Scott J. Psychosocial treatments for bipolar disorder: cost-effectiveness, mediating mechanisms, and future directions. Bipolar Disorders. 2009:11(2);110–122.</li><li>Rizvi S., Zaretsky A.E. Psychotherapy Through the Phases of Bipolar Disorder: Evidence for General Efficacy and Differential Effects. Inc. J Clin Psychol: In Session. 2007;63:491–506.</li><li>Ye B.Y., Jiang Z.Y., Li X., Cao B., Cao L.P, Lin Y., Xu G.Y., Miao G.D. Effectiveness of cognitive behavioral therapy in treating bipolar disorder: An updated meta-analysis with randomized controlled trials. Psychiatry and Clinical Neurosciences. 2016;70:351–361.</li><li>Schoeyen H.K., Kessler U., Andreassen O.A., Auestad B.H., Bergsholm P., Malt U.F., Morken G., Oedegaard K.J., Vaaler A. Treatment-Resistant Bipolar Depression: A Randomized Controlled Trial of Electroconvulsive Therapy Versus Algorithm-Based Pharmacological Treatment. Am J Psychiatry. 2015;172:41–51.</li><li>Bozzatello P., Brignolo E., De Grandi E., Bellino S. Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data. J. Clin. Med. 2016;5(67):1-26</li></rich-text></ol>
      </div>
    </div>
    <!-- END Treatment Variability in Bipolar Disorder -->
  </div>
</div></body>